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lifestyle advice for women who are overweight or
obese: the LIMIT randomised trial
Jodie M Dodd1,2*, Sharmina Ahmed3,4, Jonathan Karnon5, Wendy Umberger3,4, Andrea R Deussen1, Thach Tran1,
Rosalie M Grivell1,2, Caroline A Crowther1,6, Deborah Turnbull7, Andrew J McPhee8, Gary Wittert9, Julie A Owens1,
Jeffrey S Robinson1 and For the LIMIT Randomised Trial GroupAbstract
Background: Overweight and obesity during pregnancy is common, although robust evidence about the economic
implications of providing an antenatal dietary and lifestyle intervention for women who are overweight or obese is
lacking.
We conducted a health economic evaluation in parallel with the LIMIT randomised trial. Women with a singleton
pregnancy, between 10+0-20+0 weeks, and BMI ≥25 kg/m2 were randomised to Lifestyle Advice (a comprehensive
antenatal dietary and lifestyle intervention) or Standard Care. The economic evaluation took the perspective of the
health care system and its patients, and compared costs encountered from the additional use of resources from time of
randomisation until six weeks postpartum. Increments in health outcomes for both the woman and infant were
considered in the cost-effectiveness analysis. Mean costs and effects in the treatment groups allocated at randomisation
were compared, and incremental cost effectiveness ratios (ICERs) and confidence intervals (95%) calculated.
Bootstrapping was used to confirm the estimated confidence intervals, and to generate acceptability curves representing
the probability of the intervention being cost-effective at alternative monetary equivalent values for the outcomes
avoiding high infant birth weight, and respiratory distress syndrome. Analyses utilised intention to treat principles.
Results: Overall, the increase in mean costs associated with providing the intervention was offset by savings associated
with improved immediate neonatal outcomes, rendering the intervention cost neutral (Lifestyle Advice Group
$11261.19±$14573.97 versus Standard Care Group $11306.70±$14562.02; p=0.094). Using a monetary value of $20,000
as a threshold value for avoiding an additional infant with birth weight above 4 kg, the probability that the antenatal
intervention is cost-effective is 0.85, which increases to 0.95 when the threshold monetary value increases to $45,000.
Conclusions: Providing an antenatal dietary and lifestyle intervention for pregnant women who are overweight or
obese is not associated with increased costs or cost savings, but is associated with a high probability of cost
effectiveness. Ongoing participant follow-up into childhood is required to determine the medium to long-term
impact of the observed, short-term endpoints, to more accurately estimate the value of the intervention on risk of
obesity, and associated costs and health outcomes.
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It has been estimated that in excess of 1.46 billion adults
[1], and 170 million children [2] across the globe are
obese. Obesity is a well-recognised contributor to the
overall global burden of disease [3], associated with a
range of adverse health outcomes including cardiovascu-
lar disease, type-2 diabetes and several cancers. When
compared with individuals of normal body mass index,
obesity has been conservatively estimated to increase the
costs of health care by 30% for individuals who are
obese, compared with those of normal body mass index
(BMI) [4]. Furthermore, obesity is estimated to result in
more than 36 million disability-adjusted life-years [5],
and to contribute directly to in excess of 3.4 million
deaths annually [6].
The financial costs of obesity are substantial, an
Australian report estimating approximately $21 billion
annually in 2005 [7], further increasing to more than
$58 billion per annum in 2008 [8]. Using a broader con-
cept of “cost” to include measures of collective well-
being, it has been estimated that obesity accounts for
$120 billion annually, or 8% of Australia’s national an-
nual productivity [9]. Data from the United States indi-
cate $147 billion dollars, or 10% of the country’s total
health care expenditure was spent on treatment of obesity
related complications in 2006 [10], with projections indi-
cating a doubling of costs each decade, representing up to
18% of total health-care expenditure by 2030 [11].
Obesity represents a significant health burden for
women and their infants during pregnancy and child-
birth, with almost 50% of women having a BMI above
25 kg/m2 on entering pregnancy [12-14]. The effects of
high maternal BMI on pregnancy and infant health have
been well documented, the risks of adverse outcomes in-
creasing with increasing maternal BMI [15-19]. While
the economic implications associated with obesity have
been relatively well described in non-pregnant settings
[4,6-8], there is more limited information available relat-
ing to the healthcare costs associated with obesity during
pregnancy. The limited available literature indicates
maternal overweight and obesity to be associated with
increased cost of healthcare, including prolonged hos-
pitalisation and neonatal nursery care, when compared
with women of normal BMI [20-24], estimated to be
23% higher among women who are overweight, and in-
creasing further to 37% greater among women who are
obese [22].
There is considerable research interest in the evalu-
ation of antenatal interventions provided to women who
are overweight or obese to limit gestational weight gain
[25,26]. However, to our knowledge, there is little robust
information available evaluating the economic implica-
tions of providing these interventions, either at an indi-
vidual or population level. The aim of this pre-specifiedanalysis was to evaluate the economic costs and conse-
quences of providing an antenatal lifestyle intervention
for women who are overweight or obese, conducted
within the context of the LIMIT randomised trial [27].
Methods
An economic evaluation was conducted in conjunction
with the LIMIT randomised trial. The protocol [28] and
clinical findings from the LIMIT trial have been pub-
lished in detail previously [27,29,30]. Briefly, eligible
women with a singleton pregnancy and BMI ≥25 kg/m2,
who were between 10+0 and 20+0 weeks’ gestation, were
recruited from the three major metropolitan maternity
hospitals within Adelaide, South Australia. All women
provided written informed consent, following approval
from the ethics committee at each collaborating hospital
including Women’s and Children’s Health Network
HREC, Human Research Ethics Committee (TQEH/
LMH/MH) and Southern Adelaide Clinical HREC. At the
time of their first antenatal visit, all women had their
height and weight measured, and BMI calculated. Women
were then allocated a study number and randomised to
receive either ‘Lifestyle Advice’ or ‘Standard Care’.
Women randomised to receive Lifestyle Advice partic-
ipated in a comprehensive dietary and lifestyle interven-
tion over the course of their pregnancy, which included
a combination of dietary, exercise and behavioral strat-
egies, delivered by a research dietician and trained re-
search assistants, as described previously [27]. Within
two weeks of randomisation, women attended a plan-
ning session with a research dietician. The information
presented was subsequently reinforced during contact
with the research dietician at 28 weeks’ gestation, and
with trained research assistants (via telephone call at 22,
24, and 32 weeks’ gestation and a face-face visit at
36 weeks’ gestation).
Women randomised to receive Standard Care contin-
ued their pregnancy care according to local hospital
guidelines, which did not include routine provision of
dietary, lifestyle and behavioural advice related to diet or
gestational weight gain.
The economic evaluation took the perspective of the
health care system, and compared the costs directly as-
sociated with the additional use of resources from the
time of randomisation until six weeks postpartum.
Health outcomes for both the woman and her infant
were considered in the clinical trial, but only those out-
comes for which the intervention achieved a statistically
significant improvement are included in the cost-
effectiveness analysis, namely high infant birth weight
and respiratory distress syndrome. Costs of outpatient
occasions of service were calculated as the number of
occasions each service was encountered, multiplied by
the unit cost for that service. Table 1 presents the unit
Table 1 Unit costs of providing an antenatal lifestyle
intervention for women who are overweight/obese
Item Unit Cost
(Australian dollars)
Antenatal Clinic Visit (Doctor or Midwife)* $217
Antenatal General Practitioner Visit+ $70.30
Antenatal Anaesthetic Visit* $184
Antenatal Physician Visit* $217
Diabetes Educator Visit* $217
Provision Lifestyle Intervention* $195
Service encounters collected from the trial data for all women randomised.
Unit costs were derived from the hospital cost databases (*) and the Medicare
Benefits Schedule (+). Patient-level costings were available for all
inpatient episodes.
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data were collected for all women randomised, including
general practitioner or obstetrician/physician visits, mid-
wifery visits, antenatal anaesthetist consultation, dietician
visits, and antenatal emergency department attendance.
Unit costs for these items were taken from hospital cost
databases and the Medicare Benefits Schedule. Patient-
level inpatient costs for the woman (including delivery),
and neonatal care for the infant were available for each
woman randomised to the trial utilising computerised in-
patient cost information systems.
Mean costs and effectives in the treatment groups allo-
cated at the time of randomisation were compared, and
incremental cost effectiveness ratios (ICERs) and confi-
dence intervals (95%) calculated. Bootstrapping (using
1,000 resamples) was used to confirm the estimated confi-
dence intervals, and to generate acceptability curves that
represent the probability of the intervention being cost-
effective at alternative monetary equivalent values for the
main outcomes (avoiding high infant birth weight, and
avoiding infant respiratory distress syndrome) [31].
Health related quality of life of the woman was assessed
at baseline and at regular intervals to 4 months post-
partum, by self-completion of the SF36-Health Survey
Questionnaire [32]. The 36 items were combined into
eight multi-item summary scores, and the Bayesian non-
parametric conversion algorithm was used to generate
health-related quality of life (utility) weights on a 0 (dead)
to 1 (full health) scale [33]. Differences in utility profiles
over the trial follow-up period were compared between
the intervention and control group.
Consistent with the primary analysis of the LIMIT trial
[27], economic analyses were adjusted for the stratification
variables BMI category (25.0-29.9 kg/m2 vs ≥30.0 kg/m2),
parity (parity 0 vs parity 1 or more), and centre of recruit-
ment, and additionally for maternal age, and socio-
economic status. All data were analysed according to the
original treatment assignment using intention to treat
principles.Results
Of the 2,212 women randomised to the LIMIT trial,
1,108 were randomised to the Lifestyle Advice Group,
and 1,104 to the Standard Care Group. There were no
statistically significant differences in the baseline charac-
teristics of women randomised between the two treatment
groups (Table 2) [27], or in health service encounters, with
the exception of visits to the diabetes educator which were
increased in women receiving Lifestyle Advice (Table 3).
For clinical infant outcomes, as reported previously, in-
fants born to women following lifestyle advice were sig-
nificantly less likely to have birth weight above 4.0 kg
(Lifestyle Advice 164/1075 (15.22%) versus Standard
Care 201/1067 (18.79%); aRR 0.82; 95% CI 0.68 to 0.99;
Number Needed to Treat (NNT) 28; 95% CI 15 to 263;
p = 0.04) [27]. Furthermore, infants born to women fol-
lowing lifestyle advice were significantly less likely to
have birth weight above 4 · 5 kg (2 · 15% versus 3 · 69%;
aRR 0 · 59; 95% CI 0 · 36 to 0 · 98; p = 0 · 04), or respira-
tory distress syndrome (1 · 22% versus 2 · 57%; aRR 0 ·
47; 95% CI 0 · 24 to 0 · 90; p = 0 · 02), particularly moder-
ate or severe disease, and had a shorter length of
postnatal hospital stay (3.94 ± 7.26 days versus 4.41 ±
9.87 days; adjusted ratio of means 0.89; 95% CI 0.82-0.97;
p = 0.006) when compared with infants born to women
who received standard care [30]. No significant differences
in the health-related quality of life (utility) of women were
identified between the two treatment groups over the
follow-up period.
Health service use and direct outpatient- and inpatient
costs for study participants
The mean cost associated with providing the Lifestyle
Advice was $320.12 ± $130.97. Mean antenatal outpatient
costs were $83.40 higher for women randomised to the
Lifestyle Advice Group, compared with women receiv-
ing Standard Care (Lifestyle Advice Group $2116.39 ±
$895.14 versus Standard Care $2032.99 ± $805.63;
p = 0.022) (Table 4). However, mean costs were lower,
albeit not reaching statistical significance, for women
in the Lifestyle Advice Group, reflecting a mean of
$281.01 savings in inpatient costs (Lifestyle Advice Group
$6125.04 ± $4640.78 versus Standard Care Group
$6404.05 ± $5274.54; p = 0.185), and $168.02 savings
in infant hospitalisation costs (Lifestyle Advice Group
$2699.64 ± $13068.48 versus Standard Care Group
$2867.66 ± $12344.64; p = 0.756).
Overall, therefore, the increase in mean costs asso-
ciated with providing the intervention was offset by
savings associated with improved immediate neonatal
outcomes, rendering the intervention cost neutral
(Lifestyle Advice Group $11261.19 ± $14573.97 ver-
sus Standard Care Group $11306.70 ± $14562.02;
p = 0.094).
Table 2 Baseline characteristics at trial entry [27]
Characteristic Lifestyle advice Standard care Total
(N = 1105**) (N = 1097**) (N = 2202**)
Maternal Age (Years)* 29.3 (5.4) 29.6 (5.6) 29.4 (5.5)
Gestational Age at Entry (Weeks)+ 14.0 (11.9-17.0) 14.1 (11.9-17.0) 14.1 (11.9-17.0)
Body Mass Index (kg/m2)+ 31.0 (28.1-35.9) 31.1 (27.7-35.6) 31.1 (27.9-35.8)
Body Mass Index Category#
BMI 25.0-29.9 458 (41.4) 468 (42.7) 926 (42.1)
BMI 30.0-34.9 326 (29.5) 318 (29.0) 644 (29.2)
BMI 35.0-39.9 202 (18.3) 183 (16.7) 385 (17.5)
BMI > =40.0 119 (10.8) 128 (11.7) 247 (11.2)
Public Patient# 1081 (97.8) 1067 (97.3) 2148 (97.5)
Weight (kg)* 88.6 (17.3) 88 · 2 (17.6) 88.4 (17.4)
Height (cm)* 164.9 (6.6) 164 · 8 (6.5) 164.8 (6.6)
Race#
Caucasian 995 (90.0) 998 (91.0) 1993 (90.5)
Asian 26 (2.4) 34 (3.1) 60 (2.7)
Indian 40 (3.6) 35 (3.2) 75 (3.4)
Other 44 (4.0) 30 (2.7) 74 (3.4)
Smoker# 154 (13.9) 126 (11.5) 280 (12.7)
Nulliparous# 457 (41.4) 441 (40.2) 898 (40.8)
Previous Preterm Birth# 57 (5.2) 59 (5.4) 116 (5.3)
Previous Pre-eclampsia# 46 (4.2) 51 (4.6) 97 (4.4)
Previous Stillbirth# 13 (1.2) 6 (0.5) 19 (0.9)
Previous Neonatal Death# 11 (1.0) 7 (0.6) 18 (0.8)
Previous Caesarean Section# 197 (17.8) 214 (19.5) 411 (18.7)
Family History of Diabetes# 288 (26.1) 290 (26.4) 578 (26.2)
Family History of Hypertension# 389 (35.2) 369 (33.6) 758 (34.4)
Family History of Heart Disease# 187 (16.9) 179 (16.3) 366 (16.6)
Index of Socio-economic Disadvantage^
Unknown 2 (0.2) 1 (0.1) 3 (0.1)
Quintile 1 (Most Disadvantaged) 340 (30.8) 321 (29.3) 661 (30.0)
Quintile 2 271 (24.5) 264 (24.1) 535 (24.3)
Quintile 3 173 (15.7) 174 (15.9) 347 (15.8)
Quintile 4 150 (13.6) 178 (16.2) 328 (14.9)
Quintile 5 (Least Disadvantaged) 169 (15.3) 159 (14.5) 328 (14.9)
* = mean and standard deviation.
+ = median and interquartile range.
# = number and %.
^= Socioeconomic index as measured by SEIFA.
** = Includes all women randomised who did not withdraw consent to use their data.
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providing lifestyle advice
The unadjusted bootstrapped estimate of the difference
in the proportion of infants with birth weight above 4 kg
was 0.019 (95% CI 0.011 to 0.025), and infant respiratory
distress syndrome was 0.0123 (95% CI 0.009 to 0.017).
The incremental cost effectiveness ratio in preventingone additional infant with birth weight above 4 kg was
$2395.26 (95% CI $2198 to $2411), and in preventing
one additional infant with moderate to severe respiratory
distress syndrome was $3700 (95% CI $3589 to $3755).
Figures 1 and 2 represent the probability that provid-
ing an antenatal lifestyle intervention is cost-effective, in
preventing both birth weight above 4 kg and moderate
Table 3 Health services utilisation from randomisation to 6 weeks post-partum
Service Lifestyle advice Standard care Adjusted treatment
effect (95% CI)
Adjusted
P valueN = 1,105 N = 1,097
Antenatal Services
Antenatal Clinic Visit* 7.47 (±2.68) 7.38 (±2.65) 0.09 (−0.15 to 0.31) 0.46
General Practitioner Visit* 1.09 (±2.66) 1.12 (±2.74) −0.05 (−0.28 to 0.18) 0.67
Antenatal Anaesthetic Visit* 0.21 (±0.45) 0.22 (±0.45) −0.01 (−0.49 to 0.02) 0.49
Antenatal Physician Visit* 0.65 (±1.52) 0.57 (±1.44) −0.08 (−0.05 to 0.20) 0.24
Diabetes Educator Visit* 0.38 (±1.40) 0.25 (±0.99) −0.14 (−0.24 to 0.03) 0.01
Birthing Services
Induction of Labour+ 390 (36.25) 378 (35.39) 1.03 (0.92 to 1.15) 0.63
Caesarean birth+ 370 (34.46) 389 (36.50) 0.95 (0.85 to 1.06) 0.34
Neonatal Services
Admission to neonatal nursery+ 394 (36.61) 385 (36.05%) 1.00 (0.90 to 1.12) 0.99
Need for respiratory support+ 65 (6.09) 77 (7.20%) 0.84 (0.61 to 1.15) 0.27
* = Data presented as mean and standard deviation.
+ = Data presented as number and percentage.
Treatment effect represents adjusted difference in means (or relative risk ratio) with 95% confidence intervals.
Adjusted analyses included the stratification variables BMI category, parity and centre, in addition to adjustment for maternal age, and socioeconomic status.
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equivalent monetary values.
If a value of $20,000 is used as a threshold value for
avoiding an additional infant with birth weight above 4 kg,
the probability of the intervention being cost-effective is
0.85, compared with 0.15 in providing standard care (i.e. 1
minus the probability of cost-effectiveness for the inter-
vention). This probability of intervention cost-effectiveness
reaches almost 0.95 for the Lifestyle Advice Group if the
maximum threshold willingness to pay increases from
$20,000 to $45,000. Using the same threshold value of
$20,000 for avoiding an additional infant with moderateTable 4 Cost of health services utilisation after randomisation
Service component Lifestyle advice
N = 1,105
Maternal Outpatient Services
Antenatal Clinic Visit $1580.47 ($626.50)
(Obstetrician/Physician/Midwife)
General Practitioner Visit $118.97 ($204.49)
Antenatal Anaesthetic Visit $38.41 ($83.16)
Diabetes Educator Visit $74.42 ($289.80)
Emergency Department Presentation $305.06 ($466.84)
Total Outpatient Services $2116.39 ($895.14)
Provision of Antenatal Dietary & Lifestyle Advice $320.12 ($130.97)
Maternal Inpatient Services $6125.04 ($4640.78)
Neonatal Inpatient Services $2699.64 ($13068.48)
Total Costs Incurred $11261.19 ($14573.97)
Data presented as mean and standard deviation.
Treatment effect represents adjusted difference in means with 95% confidence inte
Adjusted analyses included the stratification variables BMI category, parity and centor severe respiratory distress syndrome, the probability
of cost-effectiveness is 0.64 in providing lifestyle advice.
Additionally if we consider the maximum threshold value
as $45,000, the probability of cost-effectiveness increases
from 0.64 to nearly 0.73 for the Lifestyle Advice Group.
Discussion
Our randomised trial is the largest reported to date evalu-
ating the effect of an antenatal lifestyle intervention for
women who are overweight or obese during pregnancy,
and the first to report a robust economic evaluation of the
associated costs and consequences. The findings of thisfor women and their infants
Standard care Adjusted treatment effect
(95% CI)
Adjusted
P valueN = 1,097
$1558.16 ($625.02) $22.30 (−$27.05 to $65.39) 0.416
$115.42 ($210.07) $3.55 (−$14.33 to $16.59) 0.689
$40.83 ($82.48) -$2.43 (−$8.58 to $3.25) 0.477
$47.47 ($203.46) $26.95 ($7.24 to $49.11) 0.008
$272.18 ($380.69) $32.88 (−$6.92 to $55.68) 0.127
$2032.99 ($805.63) $83.40 ($38.25 to $140.50) 0.022
N/A N/A N/A
$6406.05 ($5274.54) -$281.01 (−$289.31 to $448.38) 0.185
$2867.66 ($12344.64) -$168.02 (−$748.22 to $18.47) 0.756
$11306.70 ($14562.02) -$45.51 (−$1349.26 to $1003.54) 0.094
rvals.
re, in addition to adjustment for maternal age, and socioeconomic status.
Figure 1 Cost-effectiveness acceptability curve for infant birth
weight below 4 kg. Legend: Red line represents the cost
effectiveness acceptability of achieving infant birth weight below
4 kg in the Standard Care Group; Blue line represents the cost
effectiveness acceptability of achieving infant birth weight below
4 kg in the Lifestyle Advice Group.
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large-scale randomised trial indicate that the provision of
an antenatal dietary and lifestyle intervention for pregnant
women who are overweight or obese is not associated
with statistically significantly increased costs or cost sav-
ings. While providing access to the intervention was asso-
ciated with an increase in antenatal and dietician costs,
this was offset by the savings associated with improved
immediate infant birth outcomes and reduced hospitalisa-
tion costs. Using a monetary value of $20,000 as a thresh-
old value for avoiding an additional infant with birth
weight above 4 kg, the probability of cost-effectiveness of
providing the antenatal intervention was 0.85, increasing
to 0.95 with a monetary value of $45,000.
While the economic implications associated with over-
weight and obesity among non-pregnant individuals has
been relatively well described [4,6-8], there is moreFigure 2 Cost-effectiveness acceptability curve for preventing
one infant developing moderate to severe respiratory distress
syndrome. Legend: Red line represents the cost effectiveness
acceptability of preventing one infant developing moderate to
severe respiratory distress syndrome in the Standard Care Group;
Blue line represents the cost effectiveness acceptability of
preventing one infant developing moderate to severe respiratory
distress syndrome in the Lifestyle Advice Group.limited information available relating to the health care
costs associated with obesity during pregnancy. How-
ever, available literature indicates maternal overweight
and obesity to be associated with increased costs of pro-
viding antenatal care, increased number of admissions
and length of hospitalisation, and an overall increase in
health care cost, when compared with women of normal
BMI [20-24], reflecting in part an increase in the risk of
obesity related maternal and infant complications [20].
Specifically, the mean total costs associated with preg-
nancy and postpartum care have been estimated to be
23% higher among women who are overweight, increas-
ing to 37% higher among women who are obese, when
compared with women of normal BMI [22], with sugges-
tions that interventions costing less than £1171 per per-
son could be cost effective in reducing healthcare
utilisation costs among pregnant women who are obese
[22]. The cost of providing dietary and lifestyle advice as
described in the LIMIT randomised trial was approxi-
mately $320, or £179 per woman randomised, well below
the above threshold.
The equally important and potentially more significant
medium to longer-term implications of providing such a
cost-neutral and effective antenatal intervention lies in
the well-described association between high infant birth
weight and subsequent risk of both childhood [34,35]
and adulthood overweight and obesity [36,37], derived
from several population-based cohort studies. Popula-
tion cohorts have also identified consequent associations
between high infant birth weight and subsequent cardio-
metabolic risk factors, including higher blood pressure,
among children [38] which may persist into early adult-
hood [39]. Observational data from the United States in-
volving 7,738 adolescents [40] highlights a significantly
higher prevalence of obesity among children with birth
weight above 4 kg. While children of high birth weight
represented 12% of the cohort, this was disproportion-
ately increased among children who were obese at age
14 years, where 36% of individuals had birth weight over
4 kg [40].
The economic implications associated with childhood
obesity are considerable [41], with data from Australia
identifying medical costs within the first five years of
schooling to be $9.8 million greater for overweight or
obese children at age 5 years, when compared with chil-
dren of normal BMI [42]. Economic data from the
United States indicate an increase in use of prescription
medication, and both emergency and outpatient presen-
tations among children who are overweight or obese,
reflecting a cost of $14.1 billion annually [43], increasing
by another $238 million per annum when accounting for
increased inpatient admissions [44]. Conservative esti-
mates suggest medical costs alone which are directly at-
tributable to high childhood BMI are approximately
Dodd et al. BMC Obesity  (2015) 2:14 Page 7 of 9$6.24 billion, with the loss of more than 2 million quality
adjusted life years [41].
The medium to longer-term consequences of obesity
in adulthood are substantial, with obesity considered the
sixth most important factor contributing the global bur-
den of disease [3], accounting for approximately 3.4 mil-
lion adult deaths annually [6], through an increased risk
of hypertension, cardiovascular disease, type-2 diabetes
and malignancy [3]. The economic implications of treat-
ing complications related to adult obesity have variably
been estimated at more than $58 billion, with $35.6 bil-
lion reflecting indirect costs [45]. Projections from the
US highlight an increase in the proportion of total
health-care expenditure to treat obesity and its compli-
cations [11], although as highlighted by others, direct
international comparisons are exceedingly difficult [46].
There are limitations to our study. As reported previ-
ously [27], our trial population was predominantly of
white Caucasian background and of high social disad-
vantage. Furthermore, 60% of eligible women declined
to participate, reflecting both a lack of interest and time
due to other commitments. The demographic character-
istics of the women who participated in the LIMIT trial
are similar to those of the broader population of women
giving birth in South Australia [47], and therefore pro-
vide reassurance that our findings have wider clinical ap-
plicability. However, the transferability of the findings of
our economic evaluation will likely vary with the similar-
ities to both our trial population and health care system.
While we used a standard assessment of social disadvan-
tage in the SEIFA index, we were not able to assess in
more detail the effects of occupation and household in-
come. Furthermore, the analysis took the perspective of
the health care institution, limiting our ability to evalu-
ate household opportunity costs and financial implica-
tions from a societal perspective.
Conclusions
Clearly, prevention, rather than treatment of obesity and
obesity related complications should be the goal. Increas-
ingly, there is recognition that the intra-uterine environ-
ment has a key role in the development of later health and
disease [48], and therefore represents a critical period in
the subsequent programming of obesity. Any antenatal
intervention which successfully reduce the risk of high in-
fant birth weight as was demonstrated in the LIMIT ran-
domised trial [27], and particularly those which are cost
effective as reported here, represent a public health strat-
egy of significant potential in tackling the increasing prob-
lem of overweight and obesity, both in the short and
longer-term [49,50]. Ongoing follow-up of participants
into childhood will therefore be of great importance to de-
termine the longer-term impact of the intervention on risk
of obesity, and the associated economic implications.Competing interests
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